JP2020519660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519660A5 JP2020519660A5 JP2019563125A JP2019563125A JP2020519660A5 JP 2020519660 A5 JP2020519660 A5 JP 2020519660A5 JP 2019563125 A JP2019563125 A JP 2019563125A JP 2019563125 A JP2019563125 A JP 2019563125A JP 2020519660 A5 JP2020519660 A5 JP 2020519660A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer
- item
- combinations
- delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022160828A JP2022176316A (ja) | 2017-05-16 | 2022-10-05 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| JP2025100020A JP2025123379A (ja) | 2017-05-16 | 2025-06-16 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506995P | 2017-05-16 | 2017-05-16 | |
| US62/506,995 | 2017-05-16 | ||
| PCT/US2018/032755 WO2018213302A1 (en) | 2017-05-16 | 2018-05-15 | Compositions and methods for treating cancer with atypical braf mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160828A Division JP2022176316A (ja) | 2017-05-16 | 2022-10-05 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020519660A JP2020519660A (ja) | 2020-07-02 |
| JP2020519660A5 true JP2020519660A5 (enExample) | 2021-07-26 |
| JP7405408B2 JP7405408B2 (ja) | 2023-12-26 |
Family
ID=64274828
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563125A Active JP7405408B2 (ja) | 2017-05-16 | 2018-05-15 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| JP2022160828A Withdrawn JP2022176316A (ja) | 2017-05-16 | 2022-10-05 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| JP2025100020A Pending JP2025123379A (ja) | 2017-05-16 | 2025-06-16 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022160828A Withdrawn JP2022176316A (ja) | 2017-05-16 | 2022-10-05 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| JP2025100020A Pending JP2025123379A (ja) | 2017-05-16 | 2025-06-16 | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210085663A1 (enExample) |
| EP (1) | EP3624896A4 (enExample) |
| JP (3) | JP7405408B2 (enExample) |
| CN (2) | CN116036278B (enExample) |
| AU (2) | AU2018269982B2 (enExample) |
| BR (1) | BR112019024007A2 (enExample) |
| CA (1) | CA3063614A1 (enExample) |
| MX (1) | MX2019013634A (enExample) |
| WO (1) | WO2018213302A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037456A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| IL270224B1 (en) | 2017-05-02 | 2024-04-01 | Novartis Ag | Combination therapy employing trametinib and a defined raf inhibitor |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN109771436A (zh) * | 2019-03-06 | 2019-05-21 | 康赋葆(深圳)生物医药科技有限公司 | 四氢姜黄素与卡培他滨联合治疗大肠癌的应用 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| US20220168250A1 (en) * | 2019-05-16 | 2022-06-02 | Eli Lilly And Company | TRIPLE COMBINATION OF AN ERK1/2 INHIBITOR WITH A BRAF INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREATMENT OF BRAFv6ooE COLORECTAL CANCER |
| CN113966336B (zh) | 2019-06-06 | 2023-11-07 | 和记黄埔医药（上海）有限公司 | 三环类化合物及其用途 |
| GB201913121D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| GB201913124D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| GB201913123D0 (en) * | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
| CN110538316B (zh) * | 2019-10-17 | 2021-10-15 | 滨州医学院 | 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物 |
| WO2021142144A1 (en) | 2020-01-10 | 2021-07-15 | Immuneering Corporation | Mek inhibitors and therapeutic uses thereof |
| EP4106756A1 (en) * | 2020-02-18 | 2022-12-28 | Novartis AG | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc |
| WO2022179568A1 (en) * | 2021-02-25 | 2022-09-01 | Westlake Therapeutics (Hangzhou) Co., Limited | Neoantigenic peptide and its use for treating braf gene mutation related diseases |
| EP4304592A1 (en) * | 2021-03-09 | 2024-01-17 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| KR20240041917A (ko) * | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2023049798A1 (en) * | 2021-09-22 | 2023-03-30 | Henry Ford Health System | Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009077712A (ja) * | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験 |
| EP2882442B1 (en) * | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| EP3626309B1 (en) * | 2012-08-13 | 2023-03-08 | The Rockefeller University | Lxrbeta agonist for the treatment of cancer |
| PT2976106T (pt) * | 2013-03-21 | 2021-05-26 | Array Biopharma Inc | Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor |
| PH12015502260B1 (en) * | 2013-03-29 | 2022-11-16 | Biomed Valley Discoveries Inc | C. novyi for the treatment of solid tumors in humans |
| ES2733929T3 (es) * | 2013-07-12 | 2019-12-03 | Piramal Entpr Ltd | Una combinación farmacéutica para el tratamiento del melanoma |
| EP3082779B1 (en) * | 2013-12-20 | 2023-06-07 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
| US11007183B2 (en) * | 2013-12-20 | 2021-05-18 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors |
| AU2014368927B2 (en) * | 2013-12-20 | 2018-10-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of CDK and ERK inhibitors |
| WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
| US20160310477A1 (en) * | 2013-12-20 | 2016-10-27 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type 1 and erk inhibitors |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| RU2722784C2 (ru) * | 2013-12-20 | 2020-06-03 | Байомед Вэлли Дискавериз, Инк. | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf |
| EP3169797B2 (en) * | 2014-07-14 | 2025-02-19 | Universität Zürich Prorektorat MNW | Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor |
| WO2016025650A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| US10751332B2 (en) * | 2015-06-15 | 2020-08-25 | Asana Biosciences, Llc | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer |
| AU2016291161A1 (en) * | 2015-07-08 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using SLNCR isoforms |
-
2018
- 2018-05-15 MX MX2019013634A patent/MX2019013634A/es unknown
- 2018-05-15 EP EP18801345.2A patent/EP3624896A4/en active Pending
- 2018-05-15 JP JP2019563125A patent/JP7405408B2/ja active Active
- 2018-05-15 CN CN202210881186.0A patent/CN116036278B/zh active Active
- 2018-05-15 AU AU2018269982A patent/AU2018269982B2/en active Active
- 2018-05-15 CA CA3063614A patent/CA3063614A1/en active Pending
- 2018-05-15 WO PCT/US2018/032755 patent/WO2018213302A1/en not_active Ceased
- 2018-05-15 BR BR112019024007-1A patent/BR112019024007A2/pt active IP Right Grant
- 2018-05-15 CN CN201880040655.8A patent/CN110799245B/zh active Active
- 2018-05-15 US US16/613,480 patent/US20210085663A1/en active Pending
-
2022
- 2022-10-05 JP JP2022160828A patent/JP2022176316A/ja not_active Withdrawn
-
2024
- 2024-09-09 AU AU2024219529A patent/AU2024219529A1/en active Pending
-
2025
- 2025-06-16 JP JP2025100020A patent/JP2025123379A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519660A5 (enExample) | ||
| JP7405408B2 (ja) | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 | |
| US11679112B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
| Sherman | Targeted therapy of thyroid cancer | |
| Herrera et al. | Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma | |
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| JP2017502017A5 (enExample) | ||
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| Han et al. | In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma | |
| JP2017500320A5 (enExample) | ||
| CN101743013A (zh) | 使用整联蛋白配体治疗癌的特异疗法和药物 | |
| WO2015095831A1 (en) | Cancer treatments using combinations of mtor and erk inhibitors | |
| Rocchi et al. | The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets | |
| Miller et al. | Combination treatment options for castration-resistant prostate cancer | |
| Kochar et al. | Contemporary updates on clinical trials of antiangiogenic agents in the treatment of glioblastoma multiforme | |
| WO2014160967A2 (en) | C. novyi for the treatment of solid tumors in non-human animals | |
| Higano | New treatment options for patients with metastatic castration-resistant prostate cancer | |
| CA3118690A1 (en) | Use of tivozanib to treat subjects with refractory cancer | |
| RU2024101803A (ru) | Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf | |
| JP2012509287A (ja) | 癌を治療するためのインテグリンリガンドを用いる新規療法および医薬 | |
| US20220096436A1 (en) | Combination product for the treatment of cancer | |
| HK40086947A (zh) | 用於治疗具有非典型braf突变的癌症的组合物和方法 | |
| Wong et al. | ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer | |
| JPWO2020159822A5 (enExample) |